CBSC (Cardiac Biotech Solutions) YoY EPS Growth: 0.00% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiac Biotech Solutions YoY EPS Growth?

Cardiac Biotech Solutions CBSC YoY EPS Growth is 0.00% as of Jun. 2025.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Cardiac Biotech Solutions's YoY EPS Growth for the quarter that ended in Jun. 2025 was 0.00%.

Cardiac Biotech Solutions's Earnings per Share (Diluted) for the three months ended in Jun. 2025 was $0.00.

Cardiac Biotech Solutions YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Cardiac Biotech Solutions's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiac Biotech Solutions YoY EPS Growth Chart

Cardiac Biotech Solutions Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
YoY EPS Growth
0.00 -16.67 71.43 50.00 0.00

Cardiac Biotech Solutions Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.00 100.00 50.00 100.00 0.00

Cardiac Biotech Solutions YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Cardiac Biotech Solutions's YoY EPS Growth for the fiscal year that ended in Mar. 2025 is calculated as:

YoY EPS Growth (A: Mar. 2025 )
=(Earnings per Share (Diluted) (A: Mar. 2025 )-Earnings per Share (Diluted) (A: Mar. 2024 ))/ | Earnings per Share (Diluted) (A: Mar. 2024 ) |
=(-0.01--0.01)/ | -0.01 |
=0.00 %

Cardiac Biotech Solutions's YoY EPS Growth for the quarter that ended in Jun. 2025 is calculated as:

YoY EPS Growth (Q: Jun. 2025 )
=(Earnings per Share (Diluted) (Q: Jun. 2025 )-Earnings per Share (Diluted) (Q: Mar. 2024 )) / | Earnings per Share (Diluted) (Q: Mar. 2024 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 0.00% mean?
Cardiac Biotech Solutions (CBSC) has a YoY EPS Growth of 0.00% as of Jun. 2025. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Cardiac Biotech Solutions and its competitors.
Is Cardiac Biotech Solutions' YoY EPS Growth too high?
Cardiac Biotech Solutions' current YoY EPS Growth is 0.00%.
How does Cardiac Biotech Solutions' YoY EPS Growth compare to LUCY and NXGL?
Cardiac Biotech Solutions' YoY EPS Growth of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Medical Devices & Instruments company?
A good YoY EPS Growth depends on the Medical Devices & Instruments industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Cardiac Biotech Solutions and its competitors. Cardiac Biotech Solutions's current YoY EPS Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current YoY EPS Growth of 0.00%. The current YoY EPS Growth is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current YoY EPS Growth is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiac Biotech Solutions Business Description

Address 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.